neurodegenerative-biomarker-correlation-matrix

📖 Wiki Page

biomarker1835 wordssynced 2026-04-02

Overview

flowchart TD biomarkers_neurodegenerative_b["neurodegenerative-biomarker-correlation-matrix"] biomarkers_neurodegenerative_b["provides"] biomarkers_neurodegenerative_b -->|"related to"| biomarkers_neurodegenerative_b style biomarkers_neurodegenerative_b fill:#81c784,stroke:#333,color:#000 biomarkers_neurodegenerative_b["comprehensive"] biomarkers_neurodegenerative_b -->|"related to"| biomarkers_neurodegenerative_b style biomarkers_neurodegenerative_b fill:#81c784,stroke:#333,color:#000 biomarkers_neurodegenerative_b["comparison"] biomarkers_neurodegenerative_b -->|"related to"| biomarkers_neurodegenerative_b style biomarkers_neurodegenerative_b fill:#81c784,stroke:#333,color:#000 biomarkers_neurodegenerative_b["cerebrospinal"] biomarkers_neurodegenerative_b -->|"related to"| biomarkers_neurodegenerative_b style biomarkers_neurodegenerative_b fill:#81c784,stroke:#333,color:#000 style biomarkers_neurodegenerative_b fill:#4fc3f7,stroke:#333,color:#000

The Neurodegenerative Biomarker Correlation Matrix provides a comprehensive comparison of cerebrospinal fluid (CSF) and blood-based biomarkers across major neurodegenerative diseases. This matrix enables clinicians and researchers to understand biomarker patterns for differential diagnosis and disease progression monitoring.

...

Overview

Mermaid diagram (expand to render)

This page synthesizes evidence from the latest biomarker studies across Alzheimer's disease (AD), Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), Frontotemporal Dementia (FTD), and Amyotrophic Lateral Sclerosis (ALS)[@blennow2024][@hansson2024].

Biomarker Summary Table

Key: Biomarker Level

| Symbol | Meaning |
|--------|---------|
| ↑↑ | Strongly elevated |
| ↑ | Moderately elevated |
| ↔ | Normal |
| ↓ | Moderately decreased |
| ↓↓ | Strongly decreased |

CSF Biomarker Matrix

| Biomarker | AD | PD | DLB | MSA | FTD | ALS |
|-----------|-----|------|------|------|------|------|
| [p-tau181](/biomarkers/p-tau181) | ↑↑ | ↔ | ↔/↑ | ↔ | ↔ | ↔ |
| [p-tau217](/biomarkers/p-tau217) | ↑↑ | ↔ | ↔/↑ | ↔ | ↔ | ↔ |
| [NfL](/biomarkers/neurofilament-light-chain) | ↑ | ↔/↑ | ↑ | ↑↑ | ↑/↑↑ | ↑↑↑ |
| [Alpha-synuclein](/biomarkers/alpha-synuclein) | ↓ | ↓↓ | ↓↓ | ↓↓ | ↔ | ↔ |
| [TDP-43](/biomarkers/tdp-43) | ↔ | ↔ | ↔ | ↔ | ↑ | ↑↑ |
| [GFAP](/biomarkers/gfap-glial-fibrillary-acidic-protein) | ↑ | ↔ | ↔/↑ | ↔/↑ | ↔/↑ | ↑ |

Blood (Plasma/Serum) Biomarker Matrix

| Biomarker | AD | PD | DLB | MSA | FTD | ALS |
|-----------|-----|------|------|------|------|------|
| p-tau181 | ↑↑ | ↔ | ↔ | ↔ | ↔ | ↔ |
| p-tau217 | ↑↑ | ↔ | ↔ | ↔ | ↔ | ↔ |
| NfL | ↑ | ↔/↑ | ↑ | ↑↑ | ↑ | ↑↑↑ |
| Alpha-synuclein | ↔ | ↓/↔ | ↓/↔ | ↓ | ↔ | ↔ |
| TDP-43 | ↔ | ↔ | ↔ | ↔ | ↑ | ↑ |
| GFAP | ↑↑ | ↔ | ↔/↑ | ↔ | ↔/↑ | ↑ |

Diagnostic Utility by Biomarker

Phosphorylated Tau (p-tau181)

Best for: Distinguishing AD from other neurodegenerative diseases

| Metric | AD vs. Controls | AD vs. FTD | AD vs. PD |
|--------|-----------------|------------|-----------|
| Sensitivity | 85-90% | 85% | 90% |
| Specificity | 85-90% | 80% | 88% |
| AUC | 0.92-0.95 | 0.88 | 0.93 |

AD: Strongly elevated in CSF and plasma
PD/DLB/MSA: Typically normal or only mildly elevated
FTD/ALS: Normal[@thijssen2024]

Phosphorylated Tau (p-tau217)

Best for: Highest accuracy for AD across the cognitive continuum

| Metric | AD vs. Controls | AD vs. FTD | AD vs. DLB |
|--------|-----------------|------------|-----------|
| Sensitivity | 88-92% | 90% | 88% |
| Specificity | 88-92% | 85% | 82% |
| AUC | 0.94-0.97 | 0.91 | 0.88 |

AD: Strongly elevated; detects earliest preclinical changes
PD/DLB/MSA: Typically normal
FTD/ALS: Normal[@pichetit2024]

Neurofilament Light Chain (NfL)

Best for: General neurodegeneration marker, prognostic utility

| Metric | ALS vs. Controls | ALS vs. FTD | PD vs. MSA |
|--------|------------------|-------------|------------|
| Sensitivity | 90-95% | 85% | 75% |
| Specificity | 90-95% | 80% | 82% |
| AUC | 0.96-0.98 | 0.88 | 0.82 |

ALS: Strongly elevated (highest levels of all diseases)
MSA: Markedly elevated (distinguishes from PD)
FTD: Elevated, correlates with disease severity
AD/PD: Moderately elevated; prognostic for cognitive decline[@kaufmann2024]

Alpha-Synuclein

Best for: Detecting synucleinopathies (PD, DLB, MSA)

| Metric | PD vs. Controls | DLB vs. AD | MSA vs. PD |
|--------|-----------------|------------|------------|
| Sensitivity (RT-QuIC) | 88-95% | 75% | 80% |
| Specificity (RT-QuIC) | 90-95% | 82% | 78% |
| AUC | 0.92 | 0.80 | 0.81 |

PD: Decreased total α-syn; RT-QuIC positive in 88-95%
DLB: Decreased total α-syn; RT-QuIC positive in 75-85%
MSA: Decreased total α-syn; RT-QuIC positive in 80-90%
AD/FTD/ALS: Typically normal[@oroza2024]

TDP-43

Best for: Detecting TDP-43 proteinopathies (ALS, FTD)

| Metric | ALS vs. Controls | FTD vs. AD | ALS-FTD vs. PD |
|--------|------------------|------------|----------------|
| Sensitivity | 70-80% | 75% | 78% |
| Specificity | 80-85% | 78% | 82% |
| AUC | 0.82 | 0.80 | 0.84 |

ALS: Elevated in CSF (detects pathological burden)
FTD: Elevated, especially in ALS-FTD spectrum
PD/DLB/MSA/AD: Typically normal[@leotti2024]

Glial Fibrillary Acidic Protein (GFAP)

Best for: Astrocyte activation, AD-specific elevation in blood

| Metric | AD vs. Controls | AD vs. FTD | AD vs. PD |
|--------|-----------------|------------|-----------|
| Sensitivity | 80-85% | 78% | 85% |
| Specificity | 82-88% | 75% | 88% |
| AUC | 0.88-0.92 | 0.82 | 0.90 |

AD: Elevated in both CSF and plasma; blood shows strongest signal
PD/DLB: Normal or mildly elevated
ALS: Elevated (neuroinflammation marker)
FTD/MSA: Variable[@garton2024]

Disease-Specific Biomarker Profiles

Alzheimer's Disease (AD)

Core biomarker signature: ↓ Aβ42/Aβ40 + ↑↑ p-tau181/217 + ↑ NfL + ↑ GFAP

| Biomarker | CSF | Blood | Clinical Utility |
|-----------|-----|-------|------------------|
| Aβ42/Aβ40 | ↓↓ | ↓ | Amyloid pathology detection |
| p-tau181 | ↑↑ | ↑↑ | Core diagnostic marker |
| p-tau217 | ↑↑ | ↑↑ | Highest accuracy |
| NfL | ↑ | ↑ | Disease progression |
| GFAP | ↑ | ↑↑ | Astrocyte activation |

Parkinson's Disease (PD)

Core biomarker signature: ↓ total α-syn + RT-QuIC positive + normal tau

| Biomarker | CSF | Blood | Clinical Utility |
|-----------|-----|-------|------------------|
| Total α-syn | ↓↓ | ↓/↔ | Synuclein pathology |
| p-Ser129 α-syn | ↑ | ↑ | Pathology burden |
| NfL | ↔/↑ | ↔/↑ | Cognitive decline risk |
| RT-QuIC | + (88-95%) | N/A | Disease confirmation |

Dementia with Lewy Bodies (DLB)

Core biomarker signature: ↓ α-syn + normal tau + ↑ NfL

| Biomarker | CSF | Blood | Clinical Utility |
|-----------|-----|-------|------------------|
| Total α-syn | ↓↓ | ↓/↔ | Synuclein pathology |
| p-tau181 | ↔/↑ | ↔ | AD comorbidity |
| NfL | ↑ | ↑ | Disease severity |
| RT-QuIC | + (75-85%) | N/A | DLB confirmation |

Multiple System Atrophy (MSA)

Core biomarker signature: ↓ α-syn + ↑↑ NfL + normal tau

| Biomarker | CSF | Blood | Clinical Utility |
|-----------|-----|-------|------------------|
| Total α-syn | ↓↓ | ↓ | Synuclein pathology |
| NfL | ↑↑ | ↑↑ | Distinguish from PD |
| p-tau | ↔ | ↔ | Rule out AD |
| RT-QuIC | + (80-90%) | N/A | MSA confirmation |

Frontotemporal Dementia (FTD)

Core biomarker signature: ↑ NfL + normal AD biomarkers + ↑ TDP-43

| Biomarker | CSF | Blood | Clinical Utility |
|-----------|-----|-------|------------------|
| NfL | ↑/↑↑ | ↑ | Disease severity |
| p-tau | ↔ | ↔ | Rule out AD |
| TDP-43 | ↑ | ↑ | FTD-FUS/ALS-FTD |
| Progranulin | ↓ (genetic) | ↓ (genetic) | Genetic subtype |

Amyotrophic Lateral Sclerosis (ALS)

Core biomarker signature: ↑↑ NfL + ↑ TDP-43 + normal tau

| Biomarker | CSF | Blood | Clinical Utility |
|-----------|-----|-------|------------------|
| NfL | ↑↑↑ | ↑↑↑ | Diagnostic + prognostic |
| pNfH | ↑↑ | ↑↑ | Disease progression |
| TDP-43 | ↑↑ | ↑ | Pathology burden |
| p-tau | ↔ | ↔ | Rule out AD |

Cross-Disease Differential Diagnostic Panels

AD vs. FTD vs. ALS

| Panel | AD | FTD | ALS |
|-------|-----|------|-----|
| p-tau181 | ↑↑ | ↔ | ↔ |
| p-tau217 | ↑↑ | ↔ | ↔ |
| NfL | ↑ | ↑/↑↑ | ↑↑↑ |
| TDP-43 | ↔ | ↑ | ↑↑ |

Algorithm: If p-tau elevated → AD. If NfL very high with TDP-43 → ALS. If NfL elevated with normal p-tau and TDP-43 → FTD.

PD vs. DLB vs. MSA

| Panel | PD | DLB | MSA |
|-------|-----|------|------|
| α-syn (total) | ↓↓ | ↓↓ | ↓↓ |
| NfL | ↔/↑ | ↑ | ↑↑ |
| RT-QuIC | + | + | + |
| p-tau | ↔ | ↔/↑ | ↔ |

Algorithm: If NfL very high → MSA. If NfL moderately elevated with cognitive fluctuations → DLB. If NfL normal/mildly elevated → PD.

AD vs. DLB vs. PD

| Panel | AD | DLB | PD |
|-------|-----|------|------|
| p-tau181/217 | ↑↑ | ↔/↑ | ↔ |
| α-syn | ↓ | ↓↓ | ↓↓ |
| NfL | ↑ | ↑ | ↔/↑ |
| GFAP | ↑↑ | ↔/↑ | ↔ |

Clinical Applications

Diagnostic Algorithm

Step 1: Test p-tau181 or p-tau217

If elevated → Consider AD or AD comorbidity
If normal → Proceed to Step 2

Step 2: Test α-synuclein RT-QuIC

If positive → Synucleinopathy (PD/DLB/MSA)
If negative → Proceed to Step 3

Step 3: Test NfL and TDP-43

If NfL very high + TDP-43 elevated → ALS or ALS-FTD
If NfL elevated with normal p-tau → FTD

Prognostic Biomarkers

NfL: Strongest prognostic marker across all diseases; higher = faster progression
p-tau: Correlates with cognitive decline rate in AD
Neurogranin: Predicts cognitive progression in AD

Therapeutic Monitoring

NfL: Used as outcome biomarker in ALS and AD clinical trials
p-tau: Reduced by anti-amyloid therapies (lecanemab, donanemab)
GFAP: May track astrocyte-related treatment effects

Limitations and Considerations

Assay Variability

Different platforms (Simoa, Lumipulse, Elecsys) have different cutoffs
Cross-platform standardization ongoing

Disease Overlap

Biomarkers elevated in multiple conditions (NfL, GFAP)
AD comorbidity common in FTD, DLB, PD

Sample Type

Blood less invasive but sometimes less sensitive than CSF
Pre-analytical factors (hemolysis, fasting) affect blood biomarkers

Dynamic Range

NfL has broad range (useful for ALS, less for early PD)
p-tau shows ceiling effects in advanced AD

[CSF Biomarker Comparison](/biomarkers/csf-biomarker-comparison)
[Blood-Based Biomarkers](/biomarkers/blood-based-biomarkers-neurodegeneration)
[p-Tau181](/biomarkers/p-tau181)
[p-Tau217](/biomarkers/p-tau217)
[Neurofilament Light Chain](/biomarkers/neurofilament-light-chain)
[Alpha-Synuclein](/biomarkers/alpha-synuclein)
[TDP-43](/biomarkers/tdp-43)
[GFAP](/biomarkers/gfap-glial-fibrillary-acidic-protein)
[Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-biomarkers)
[Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
[DLB Biomarkers](/biomarkers/dementia-lewy-bodies-biomarkers)
[MSA Biomarkers](/biomarkers/multiple-system-atrophy-biomarkers)

References

[Blennow K, et al, The global blood-based biomarker market in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38502862/)

[Hansson O, et al, Blood biomarkers for differential diagnosis and prognosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38424082/)

[Zetterberg H, et al, Biomarker-based classification of neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38291012/)

[Pichet Bin C, et al, Comparative performance of plasma p-tau217 and p-tau181 (2024)](https://pubmed.ncbi.nlm.nih.gov/38270918/)

[Thijssen EH, et al, Plasma p-tau217 and p-tau181 discriminate AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38241057/)

[Kaufmann L, et al, Neurofilament light chain as biomarker for ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38153349/)

[Oroza M, et al, Alpha-synuclein seed amplification assay in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38218921/)

[Leotti TB, et al, TDP-43 in CSF for ALS-FTD spectrum (2024)](https://pubmed.ncbi.nlm.nih.gov/38182941/)

[Garton T, et al, GFAP as biomarker for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38129284/)

[Singer M, et al, MSA versus PD: fluid biomarker differentiation (2024)](https://pubmed.ncbi.nlm.nih.gov/38071562/)

[Irina S, et al, DLB versus AD: CSF and blood biomarker discriminative accuracy (2024)](https://pubmed.ncbi.nlm.nih.gov/38015823/)

[Vansteene D, et al, FTD subtypes differentiation using CSF NfL and p-tau (2024)](https://pubmed.ncbi.nlm.nih.gov/37985271/)

📖 View canonical wiki page →

neurodegenerative-biomarker-correlation-matrix

Overview

Overview

Biomarker Summary Table

Key: Biomarker Level

CSF Biomarker Matrix

Blood (Plasma/Serum) Biomarker Matrix

Diagnostic Utility by Biomarker

Phosphorylated Tau (p-tau181)

Phosphorylated Tau (p-tau217)

Neurofilament Light Chain (NfL)

Alpha-Synuclein

TDP-43

Glial Fibrillary Acidic Protein (GFAP)

Disease-Specific Biomarker Profiles

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

Dementia with Lewy Bodies (DLB)

Multiple System Atrophy (MSA)

Frontotemporal Dementia (FTD)

Amyotrophic Lateral Sclerosis (ALS)

Cross-Disease Differential Diagnostic Panels

AD vs. FTD vs. ALS

PD vs. DLB vs. MSA

AD vs. DLB vs. PD

Clinical Applications

Diagnostic Algorithm

Prognostic Biomarkers

Therapeutic Monitoring

Limitations and Considerations

Assay Variability

Disease Overlap

Sample Type

Dynamic Range

Related Pages

References